In CLL, we have previously described ibrutinib therapy as inducing cell-surface IgM and BCR adaptor protein GAB1, suggesting a compensatory response (23–25), and rewiring of the signaling pathways upon ibrutinib treatment has also been shown by others (26). Here, GAB1 is linked to B-cell chronic lymphocytic leukemia.